poh has a new board, page-61

From "The Pharma Letter"

Mr Gozlan said: “Nathan, Geert and I are delighted to join the company at this time with such a compelling technology targeting large unmet medical needs. The results from the oxymorphone patch trial, announced in October, indicate the company is well on the
way to finalising development and commercialisation of this novel and valuable product. We look forward to continuing to revamp Phosphagenics and help drive commercialization and also look forward to potential additions to the board and senior executive team in the future.”

More at:

http://www.thepharmaletter.com/article/phosphagenics-appoints-three-new-non-executive-directors